NCT07251946

Brief Summary

This retrospective study included 316 bladder cancer patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
316

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2019

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2023

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

November 19, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 26, 2025

Completed
Last Updated

November 26, 2025

Status Verified

November 1, 2025

Enrollment Period

3.7 years

First QC Date

November 19, 2025

Last Update Submit

November 19, 2025

Conditions

Bladder Cancer

Outcome Measures

Primary Outcomes (1)

  • overall survival

    2 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a confirmed diagnosis of bladder cancer

You may qualify if:

  • pathological diagnosis of bladder cancer,
  • available clinical information,
  • age \>18 years,
  • patients underwent non-contrast and enhanced abdominal CT examination within 4 weeks before cystectomy for bladder cancer.

You may not qualify if:

  • other malignancies in combination,
  • less than one month of follow-up or lack of follow-up,
  • patients with T4b stage,distant metastases (M1 stage)
  • image artefacts or poor quality of image alignment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union Hospital，Tongji Medical College，Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

November 19, 2025

First Posted

November 26, 2025

Study Start

August 1, 2019

Primary Completion

March 31, 2023

Study Completion

March 31, 2023

Last Updated

November 26, 2025

Record last verified: 2025-11

Locations

CN(1)